Dr Phadke on the Benefit of Sacituzumab Govitecan in HR+/HER2– Breast Cancer
Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.